Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 22, 2022 - Issue 5
Submit an article Journal homepage
215
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Trends in disease-modifying therapy use in patients with multiple sclerosis using a 10-year population-based cohort study in France

Soline Leblanca Univ Rennes, EHESP, CNRS, Inserm, ARENES – UMR 6051, RSMS – U 1309, F-35000 Rennes, Rennes, FranceView further author information
,
Mathilde Leforta Univ Rennes, EHESP, CNRS, Inserm, ARENES – UMR 6051, RSMS – U 1309, F-35000 Rennes, Rennes, FranceView further author information
,
Emmanuelle Le Pageb INSERM CIC-P 1414, CRC-SEP Rennes University Hospital, Rennes University, Rennes, France;c Neurology department, Rennes University Hospital, Rennes University, Rennes, FranceView further author information
,
Laure Michelb INSERM CIC-P 1414, CRC-SEP Rennes University Hospital, Rennes University, Rennes, France;c Neurology department, Rennes University Hospital, Rennes University, Rennes, FranceView further author information
&
Emmanuelle Leraya Univ Rennes, EHESP, CNRS, Inserm, ARENES – UMR 6051, RSMS – U 1309, F-35000 Rennes, Rennes, France;b INSERM CIC-P 1414, CRC-SEP Rennes University Hospital, Rennes University, Rennes, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8424-4499View further author information
ORCID Icon
Pages 411-418 | Received 06 Jan 2022, Accepted 31 Mar 2022, Published online: 05 Apr 2022

References

  • McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325(8):765–779.
  • Leblanc S, Roux J, Tillaut H, et al. Disease-modifying therapy usage in patients with multiple sclerosis in France: a 6-year population-based study. Rev Neurol (Paris). 2021;177(10):1250–1261.
  • Vermersch P, Suchet L, Colamarino R, et al. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017. Mult Scler Relat Disord. 2020;46:102521.
  • Moisset X, Fouchard AA, Pereira B, et al. Untreated patients with multiple sclerosis: a study of French expert centers. Eur J Neurol. 2021;28(6):2026–2036.
  • Tuppin P, de Roquefeuil L, Weill A, et al. French national health insurance information system and the permanent beneficiaries sample. Rev. Epidemiol. Sante Publique. 2010;58(4):286–290.
  • Martin-Latry K, Bégaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf. 2010;19(3):256–265.
  • Moulis G, Lapeyre-Mestre M, Palmaro A, et al. French health insurance databases: what interest for medical research? Rev Med Interne. 2015;36(6):411–417.
  • Palmaro A, Moulis G, Despas F, et al. Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. Fundam Clin Pharmacol. 2016 Dec;30(6):616–624.
  • Foulon S, Maura G, Dalichampt M, et al. Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data. J Neurol. 2017;264(6):1185–1192.
  • Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–481.
  • Box GE, Jenkins GM, Reinsel GC, et al. Time series analysis: forecasting and control. 5th edn. Hoboken: John Wiley and Sons; 2015.
  • Hyndman RJ, Athanasopoulos G. Forecasting: principles and practice. 2nd (Melbourne, Australia.: OTexts); 2018. OTexts.com/fpp2
  • Core Team R. R: a language and environment for statistical computing. Vienna Austria: R Foundation for Statistical Computing; 2019 [ URL https://www.R-projet.org/].
  • Roux J, Guilleux A, Lefort M, et al. Use of healthcare services by patients with multiple sclerosis in France over 2010-2015: a nationwide population-based study using health administrative data. Multiple Scler J Exp Trans Clin. 2019;5(4):2055217319896090.
  • Ng HS, Zhu F, Kingwell E, et al. Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting. Expert Rev Neurother. 2021;21(1):131–140.
  • Ha-Vinh P, Nauleau S, Clementz M, et al. Health care services and disease modifying therapies use in community-based multiple sclerosis patients: evolution from 2013 to 2015 and demographic characteristics. Presse Med. 2019;48(1 Pt 1):e1–19.
  • Koch-Henriksen N, Laursen B, Stenager E, et al. Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study. J Neurol Neurosurg Psychiatry. 2017;88(8):626–631.
  • Livingston T, Fay M, Iyer R, et al. Quantifying differences in health care consumption for the management of multiple sclerosis within privately and publicly insured health care programs. J Manag Care Spec Pharm. 2016;22(12):1385–1391.
  • Jokubaitis VG, Spelman T, Lechner-Scott J, et al. The Australian multiple sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform. PloS One. 2013;8(3):e59694.
  • Debouverie M, Laforest L, Van Ganse E, et al. Earlier disability of the patients followed in Multiple Sclerosis centers compared to outpatients Mult Scler. Multiple sclerosis (Houndmills, Basingstoke, England). 2009;15(2):251–257.
  • Wong B, Cahill J, Rizvi S. Moving Towards a Cure for MS: increased immunosuppression and striving for No Evidence of Disease Activity (NEDA). R I Med J (2013). 2018.;101(2):26–29.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.